18 reports

  • Gastrointestinal Drugs Market Trends And Strategies
  • Gastrointestinal Drugs Market Key Mergers And Acquisitions
  • Gastrointestinal Drug
  • World
  • Allergan plc
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • GASTROINTESTINAL DISORDERS, GLOBAL, KEY MARKETED PRODUCTS AND APPROVED INDICATIONS, 2016
  • Executive Summary
  • Clinical Trial
  • Gastrointestinal Drug
  • Pharmaceutical
  • Market Size
  • AstraZeneca PLC
  • Impact of drivers and challenges

Offers a wide range of drugs and pharmaceuticals for the treatment of neuroscience and gastrointestinal diseases.

  • Gastrointestinal Drug
  • Forecast
  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Unaccomplished Trials of Reflux Esophagitis (Gastroesophageal Reflux Disease)
  • Five Key Clinical Profiles

Arms Type Arm I Arm II Active Comparator Active Comparator Pantoprazole magnesium (Tecta, Surmera) is a gastrointestinal, anti ulcer agent.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Market Size
  • AstraZeneca PLC
  • Trial Results
  • ESOPHAGEAL DISEASES THERAPEUTICS, GLOBAL, TERMINATED CLINICAL TRIALS, 2015*

Mechanism of Action Lafutidine (Protecadin, Stogar) is an anti-ulcer drug and a gastrointestinal agent.

  • Clinical Trial
  • Drug Discovery And Development
  • Gastrointestinal Drug
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Clinical Trial Details
  • Contact Detail(s)

Mechanism of Action Vonoprazan fumarate (Takecab) is a novel anti-secretory drug, acts as gastrointestinal Protective Agent, formulated as tablets for the oral route of administration.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC
  • Clinical Trial Product Information

PROPORTION OF NONEROSIVE REFLUX DISEASE (NERD) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2015* PROPORTION OF NONEROSIVE REFLUX DISEASE (NERD) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2015* PROPORTION OF NONEROSIVE REFLUX DISEASE (NERD) TO

  • Clinical Trial
  • Gastrointestinal Drug
  • World
  • ALTANA AG
  • AstraZeneca PLC
  • CHAPTER IV DIGESTIVE REMEDIES DRUGS PRODUCTION AND DEMAND

THE INCIDENCE OF GASTROINTESTINAL DISEASES AROUND THE WORLD WAS ABOUT ##% OF POPULATION.

  • Gastrointestinal Drug
  • OTC
  • Pharmaceutical
  • Market Size
  • AstraZeneca PLC

For instance, Amitiza causes nausea, dyspnea, mechanical gastrointestinal obstruction, and diarrhea.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Opioid
  • World
  • AstraZeneca PLC

The usage of opioids and their adverse effects in gastrointestinal practice: a review.

  • Gastrointestinal Drug
  • Opioid
  • Therapy
  • AstraZeneca PLC
  • Merck & Co., Inc.

They have sixty plus products on market, covering categories of gastrointestinal, cardiovascular, anti-tumor, and antibiotics.

  • Gastrointestinal Drug
  • Pharmaceutical
  • China
  • Demand
  • AstraZeneca PLC
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Upper gastrointestinal endoscopy will be performed prior to drug treatment, and at the end of the ##-day study period.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Therapy
  • AstraZeneca PLC
  • Clinical Trial Profile Snapshots

Proportion of Zollinger-Ellison Syndrome (Gastrinoma) to Gastrointestinal Clinical Trials, G## Countries (%), 2016* Proportion of Zollinger-Ellison Syndrome (Gastrinoma) to Gastrointestinal Clinical Trials, G## Countries (%), 2016* In total there were ## clinical trials conducted on

  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • AstraZeneca PLC
  • Clinical Trial Profile Snapshots

Reddys under Fed Condition GDCT## NCT##, ##/ ##-## Gastrointestinal Acidity, Duodenal Ulcer, Gastric Ulcers, Reflux Esophagitis (Gastroesophageal Reflux Disease), Ulcers Completed Phase I Interventional omeprazole DR Dr.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC
  • FEATURED NEWS & PRESS RELEASES

Gastrointestinal ulcers and gastric motility disorders are common in China and have a significant patient base.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Litigation And Patent
  • AstraZeneca PLC
  • MAY 02, 2001: ASTRAZENECA RECEIVES SIX MONTHS' MARKET EXCLUSIVITY FOR PRILOSEC
  • OCT 20, 2000: JOINT FDA ADVISORY COMMITTEE CONFIRMS OTC PRILOSEC (OMEPRAZOLE) SAFETY AND EFFICACY

Gastrointestinal ulcers and gastric motility disorders are common in China and have a significant patient base.

  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Litigation And Patent
  • AstraZeneca PLC

Gastrointestinal ulcers and gastric motility disorders are common in China and have a significant patient base.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • AstraZeneca PLC
  • Clinical Trial Profile Snapshots

Gastrointestinal Disorders, Regurgitation Completed Phase IV Interventional baclofen University Hospitals Leuven Katholieke Universiteit Leuven ## Sep 2011 ## Sep 2013 ## ## ## GABAB Receptor (GABABR) Agonist Gamma-Aminobutyric Acid (GABA) B Receptor (GABBR) Official Title Clinical Trial pro

  • Cardiology
  • Gastrointestinal Drug
  • Hospital
  • Therapy
  • AstraZeneca PLC